Orchestra BioMed Holdings, Inc. (OBIO)
Data as of , from SEC Form 4 filings.
See up to 3 months of OBIO. The 7-day demo opens the 1M and 3M ranges and puts OBIO on your watchlist.
Start 7-day demoLatest OBIO insider trades
- Darren Sherman - OfficerOpen-market sale$95K
David P. Hochman - OfficerOpen-market purchase$48K
About Orchestra BioMed Holdings, Inc. (OBIO)
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
- NEW HOPE, PA
- 86
- 2023
- XNAS
https://www.orchestrabiomed.comSEC filings for OBIO on EDGAR
OBIO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 12,000 | $59K |
| Open-market sale | 3 | 45,000 | $231K |
| Tax withholding / forfeiture | 9 | 32,799 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
OBIO insider transactions (Form 4)
2074 Form 4 filings on record, the earliest from Dec 6, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Eric S. Fain - Director | Grant or award | Common Stock, par value $0.0001 per share (Common Stock) | 7,500 | $0.00 | - | |
| Eric S. Fain - Director | Grant or award | Common Stock | 7,500 | $0.00 | - | |
 Jason Aryeh - Director | Grant or award | Common Stock, par value $0.0001 per share (Common Stock) | 15,000 | $0.00 | - | |
| David P. Hochman - Officer | Grant or award | Common Stock, par value $0.0001 per share (Common Stock) | 100,000 | $0.00 | - | |
| David P. Hochman - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - | |
| PERCEPTIVE ADVISORS LLC | Open-market purchase | Common Stock | 700,000 | $2.75 | $1.93M | |
| PERCEPTIVE ADVISORS LLC | Open-market purchase | Pre-funded Warrants (right to buy) | 1,500,000 | $2.75 | $4.12M | |
| David P. Hochman - Officer | Open-market purchase | Common Stock, par value $0.0001 per share (Common Stock) | 20,000 | $2.75 | $55K | |
| RTW INVESTMENTS, LP | Open-market purchase | Pre-Funded Warrants (Right to Buy) | 3,636,363 | $2.75 | $10.00M | |
| David P. Hochman - Officer | Tax withholding / forfeiture | Common Stock, par value $0.0001 per share (Common Stock) | 34,038 | $3.14 | $107K | |
| David P. Hochman - Officer | Tax withholding / forfeiture | Common Stock | 5,671 | $3.14 | $18K | |
| David P. Hochman - Officer | Grant or award | Common Stock, par value $0.0001 per share (Common Stock) | 98,333 | $0.00 | - | |
| David P. Hochman - Officer | Grant or award | Stock Option (Right to Buy) | 147,500 | $0.00 | - | |
| Jason Aryeh - Director | Option exercise | Common Stock, par value $0.0001 per share ("Common Stock") | 11,700 | $4.30 | $50K | |
| Jason Aryeh - Director | Option exercise | Stock Option (Right to Buy) | 11,700 | $0.00 | - | |
| David P. Hochman - Officer | Open-market purchase | Common Stock, par value $0.0001 per share ("Common Stock") | 4,000 | $4.66 | $19K | |
| Andrew Lawrence Taylor - Officer | Open-market purchase | Common Stock, par value $0.0001 per share | 1,000 | $4.83 | $5K | |
| David P. Hochman - Officer | Open-market purchase | Common Stock, par value $0.0001 per share ("Common Stock") | 5,000 | $4.91 | $25K | |
| Andrew Lawrence Taylor - Officer | Tax withholding / forfeiture | Common Stock, par value $0.0001 per share | 34,403 | $5.03 | $173K | |
| Darren Sherman - Officer | Tax withholding / forfeiture | Common Stock, par value $0.0001 per share ("Common Stock") | 31,815 | $5.57 | $177K |
Recent OBIO Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Sherman Darren | Officer, Director | 15,000 | $94K | View on EDGAR | |
| Sherman Darren | Officer, Director | 15,000 |
OBIO insider trading FAQ
What is the latest insider trade for OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) had 12 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for OBIO runs to 74 Form 4 filings, the earliest from 2024-12-06. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OBIO stock?
2 insider purchases of OBIO were filed in the last 90 days, totaling $59K.
How many insiders are selling OBIO stock?
3 insider sales of OBIO were filed in the last 90 days, totaling $231K.
Where can I see OBIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OBIO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Darren Sherman view on EDGAR
- - David P. Hochman view on EDGAR
- - David P. Hochman view on EDGAR
- - Darren Sherman view on EDGAR
- - Andrew Lawrence Taylor view on EDGAR
- - Darren Sherman view on EDGAR
- - Joshua Aiello view on EDGAR
- - David Pacitti view on EDGAR
- - Eric S. Fain view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where OBIO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OBIO with a 7-day demo
- OBIO on your watchlist
- Every OBIO Form 4 filing on record
- Up to 3 months of OBIO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
